Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

MiR-146b restoration in T-large granular lymphocyte leukemia: Molecular insights for a new therapeutic strategy

Antonella Teramo, Elisa Rampazzo, Eleonora Roncaglia et al. Nov 03, 2025 pp. 2538-2538 10.1182/blood-2025-2538

Abstract INTRODUCTION T-Large Granular Lymphocyte Leukemia (T-LGLL) is a rare lymphoproliferative disorder characterized by the clonal expan...

Unexplained thrombosis and profound monocytopenia in an adolescent: Delayed diagnosis of GATA2 haploinsufficiency

Moujtaba Zahweh, Ahsan Wahab, Carlos Murga Zamalloa et al. Nov 03, 2025 pp. 6753-6753 10.1182/blood-2025-6753

Abstract Introduction: GATA2 haploinsufficiency, or MonoMAC syndrome, is an autosomal dominant disorder characterized by monocytopenia and m...

Diagnostic accuracy and challenges of AI/ML models for sickle cell disease detection in blood smears: A meta-analysis and systematic review

Harshawardhan Dhanraj Ramteke, Nimra Shafi, Sai Manohar Raju Obbani et al. Nov 03, 2025 pp. 4732-4732 10.1182/blood-2025-4732

Abstract Introduction: Sickle cell disease (SCD) is a genetic blood disorder affecting millions worldwide, requiring early and accurate diag...

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Kateryna Fedorov, Kathryn Kennedy, Erica Mittlebeeler et al. Nov 03, 2025 pp. 1666-1666 10.1182/blood-2025-1666

Abstract Background: Despite significant advances in treatment of AML over the past decade, long-term survival remains poor. The addition of...

Examining folate and B12 deficiency in patients following allogeneic transplant

Kelly Weaver, Hang Zeng, Thomas Knight et al. Nov 03, 2025 pp. 7713-7713 10.1182/blood-2025-7713

Abstract Background: Patients (pts) undergoing allogeneic hemopoietic stem cell transplant (alloHSCT) often have poor oral intake, which may...

Efficacy and safety of mini-CVD combined with venetoclax and azacitidine in acute leukemia of ambiguous lineage: A single-center retrospective study

Yan Li, Yue Shang, Kaiqi Liu et al. Nov 03, 2025 pp. 6864-6864 10.1182/blood-2025-6864

Abstract Background:Acute leukemias of ambiguous lineage (ALAL) is a rare type of hematologic malignancies with poor outcomes. Currently, th...

Utilization patterns of venetoclax-based regimens for AML in a community based setting & representative populational analyses

Natasha Amjed, Tyler Bruno, Mark Mitchell et al. Nov 03, 2025 pp. 8168-8168 10.1182/blood-2025-8168

Abstract Introduction: Azacitidine and Venetoclax was approved for older patients in 2020 ineligible for intensive chemotherapy, and it has...

Dietary serine restriction increases venetoclax efficacy in Acute Myeloid Leukemia

Mallikarjun Reddy, Alli Abolarin, Valerie Kellet et al. Nov 03, 2025 pp. 5046-5046 10.1182/blood-2025-5046

Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with relapse rates exceeding 50% and long-term survival...

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Omar Elghawy, Nishwant Swami, Ayo Falade et al. Nov 03, 2025 pp. 893-893 10.1182/blood-2025-893

Abstract Introduction: Primary central nervous system T-cell lymphoma (PCNSTL) is a rare form of PCNSL, comprising 2–8% of cases. Prognostic...

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Esperanza Martin-Sanchez, Marta Lasa, Juan-Jose Garces et al. Nov 03, 2025 pp. 366-366 10.1182/blood-2025-366

Abstract Background: Evidence suggests that CTCs are responsible for MM spreading and therefore prognostic. However, some pts unexpectedly h...

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Fernanda Santos Azevedo, Kiyomi Mashima, Ava Bidgoli et al. Nov 03, 2025 pp. 3906-3906 10.1182/blood-2025-3906

Abstract Background: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous hematologic malignancy. The identification of risk fact...

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler et al. Nov 03, 2025 pp. 3951-3951 10.1182/blood-2025-3951

Abstract Background: Bispecific T cell engagers (BTCEs) have transformed the treatment of multiple myeloma (MM) and B cell malignancies by re...

Characteristics of immune genes rearrangements in Chinese multiple myeloma patients

Donghua He, Yang Yang, Yiwei Zhou et al. Nov 03, 2025 pp. 5759-5759 10.1182/blood-2025-5759

Abstract Introduction:For improving outcomes of patients in early treatment, diverse detections were developed for prognosis prediction. Mul...

Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity

Meng Liu, Lei Zhang, Xin He et al. Nov 03, 2025 pp. 1490-1490 10.1182/blood-2025-1490

Abstract Immunotherapy, including immune checkpoint inhibitors, antagonizes many hematologic malignancies, but has transient effects on acut...

Delays in hydroxyurea initiation for patients with sickle cell disease in British Columbia

Sarah Keyes, Angelina Marinkovic, Hayley Merkeley Nov 03, 2025 pp. 7975-7975 10.1182/blood-2025-7975

Abstract Introduction: Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by abnormal hemoglobin S that polymerizes to...

Association of platelet count and mean platelet volume with clinical outcomes in pulmonary embolism: A retrospective cohort study

Laith Sorour, Tasneem Anagreh, Mohammed Faris et al. Nov 03, 2025 pp. 6669-6669 10.1182/blood-2025-6669

Abstract Introduction Mean platelet volume (MPV) and platelet count have been proposed as prognostic markers in thrombotic and bleeding diso...

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Abdul-Hamid Bazarbachi, Huihui Ma, Simon Zhen et al. Nov 03, 2025 pp. 4255-4255 10.1182/blood-2025-4255

Abstract Background: Allogeneic hematopoietic stem-cell transplantation (HSCT) is curative for adult sickle-cell disease (SCD). Yet donor so...

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma

Junnan Li, Xin Wang, Shuangnian Xu et al. Nov 03, 2025 pp. 7517-7517 10.1182/blood-2025-7517

Abstract Background:Continuous treatment is essential for achieving sustained disease control in multiple myeloma (MM). Daratumumab(Dara)-ba...

Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT)

Ju-Hyeun Kim, Scott Stryker, Peter Enzinger et al. Nov 03, 2025 pp. 2681-2681 10.1182/blood-2025-2681

Abstract Introduction: Literature suggests an increased risk of mortality in patients with solid tumors and thrombocytopenia, but data on OS...

Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma

Inna Gong, Rowena Rodrigo, Giselle Boukhaled et al. Nov 03, 2025 pp. 3567-3567 10.1182/blood-2025-3567

Abstract Introduction Chimeric antigen receptor T cell (CAR T) therapy for relapsed/refractory large B-cell lymphoma (LBCL) achieves long-ter...

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Daehun Kwag, Byung-Sik Cho, Gi June Min et al. Nov 03, 2025 pp. 1636-1636 10.1182/blood-2025-1636

Abstract Background: Apolipoprotein E (APOE) exists in three major isoforms—ε2, ε3, and ε4—which differentially influence tumor immunity by...

CⅡTA-mediated up-regulation of MHC reverses immune evasion of leukemia stem cells in refractory/relapsed AML

Chengyuan Xue, Yu Zhang, Yuping Si et al. Nov 03, 2025 pp. 1509-1509 10.1182/blood-2025-1509

Abstract Background Leukemia stem cells (LSCs) are recognized as the principal reservoir driving chemoresistance and relapse in acute myeloi...

Optimizing board exam outcomes: A structured exam preparation curriculum for hematology/oncology fellows

Sonia Godbole, Manan Shah, Rich Thompson et al. Nov 03, 2025 pp. 8219-8219 10.1182/blood-2025-8219

Abstract Background Achieving board certification is a critical marker of baseline clinical competence in early career h...

Acalabrutinib vs zanubrutinib as first-line therapy in CLL: A propensity score–matched study

Angimar Uriepero, Jose Milano, Valeria Ziegler et al. Nov 03, 2025 pp. 6333-6333 10.1182/blood-2025-6333

Abstract INTRODUCTION: Covalent Bruton tyrosine kinase inhibitors (cBTKis) have transformed the treatment paradigm of chronic lymphocytic le...

Parental perspectives on financial distress during treatment for childhood acute lymphoblastic leukemia: A qualitative report from Children's oncology group (COG) study ACCL20N1CD

Joanna Robles, Sheila Santacroce, Melissa Beauchemin et al. Nov 03, 2025 pp. 2623-2623 10.1182/blood-2025-2623

Abstract Introduction: Cancer-related financial hardship among families of children with cancer contributes to poor qual...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page